sevelamer

(redirected from Renvela)
Also found in: Dictionary.

sevelamer

 [sĕ-vel´ah-mer]
a phosphate binder used as the hydrochloride salt to reduce serum phosphorus concentrations in hyperphosphatemia associated with end-stage renal disease; administered orally.

sevelamer

A phosphate chelator used to reduce phosphorus in patients with end-stage renal disease and in chronic renal failure patients not requiring dialysis. It also reduces uric acid levels, and may be of use in patients with hyperuricaemia, uric acid nephrolithiasis and gout.

Adverse effects
Blood pressure lability (hypo- or hypertension), nausea, vomiting, dyspepsia, diarrhoea, constipation.

sevelamer

Renagel® Nephrology A chelator used to ↓ phosphorus in Pts with ESRD and in chronic renal failure Pts not requiring dialysis. See Chelation, End-stage renal disease.
References in periodicals archive ?
The Renvela brand and generic had US sales of approximately USD101 m MAT for the most recent twelve months ending in October 2018 according to IMS Health.
Selon la monographie de RENVELA[R] (Sanofi-Aventis, 2017), << On ne doit pas croquer, macher ni rompre les comprimes de RENVELA (carbonate de sevelamer) avant de les avaler.
Medications on admission included amlodipine, sensipar, hydralazine, megace, pantoprazole, thiamine, and renvela. Physical exam showed a blood pressure of 198/110 a pulse of 106.
Renvela tablets had US sales of approximately USD1.85bn for the 12 months ending August 2017, according to IMS Health.
Welchol: Daiichi Sankyo Inc, Tokyo, Japan; Colestid: Pfizer Inc, New York, New York; LoCholest: Warner Chilcott Inc, Rockaway, New Jersey; Prevalite: Upsher-Smith Laboratories, Maple Grove, Minnesota; Questran: Par Pharmaceutical, Woodcliff Lake, New Jersey; Kayexalate: Concordia International Corp, Oakville, Ontario, Canada; and Renvela and Renagel: Sanofi SA, Paris, France.
[45] Genzyme Corporation, Renvela (Sevelamer Carbonate) Package Insert, Genzyme Corporation, Cambridge, Mass, USA, 2011.
When I don't have it I feel like I'm self-destructing." Another noted a change in phosphorus levels when decreasing Renvela: "I really don't understand how you are supposed to feel."
Renvela is a next generation version of Renagel, a calcium-free metal free, non-absorbed phosphate binder, and has the added benefit of a carbonate filter.
Renvela is being developed as a next generation phosphate binder to replace Renagel (sevelamer hydrochloride), the most-prescribed phosphate binder in the United States.
M2 EQUITYBITES-October 24, 2017-Impax passes US FDA approval for generic Renvela (sevelamer carbonate) Tablets, 800 mg
Sevelamer (Renvela, Genzyme, Cambridge, Massachusetts) is a resin used to bind excess phosphate in dialysis patients with hyperphosphatemia.
The Genzyme Corporation, Cambridge, MA, announced that the European Medicines Agency's Committee for Medicinal Products (CHMP) has adopted a positive opinion for the marketing authorization of the new phosphate binder Renvela for use in patients with chronic kidney disease (CKD), including patients not on dialysis with serum phosphorous levels >1.78 mmol/L.